azelnidipine has been researched along with hydrazine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichikawa, H; Katada, K; Kokura, S; Kon, T; Manabe, H; Naito, Y; Nakabe, N; Shimozawa, M; Yoshida, N; Yoshikawa, T | 1 |
1 other study(ies) available for azelnidipine and hydrazine
| Article | Year |
|---|---|
Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.
Topics: Aorta; Azetidinecarboxylic Acid; Biphenyl Compounds; Calcium Channel Blockers; Cell Adhesion; Cell Membrane; Cyclic N-Oxides; Dihydropyridines; Dose-Response Relationship, Drug; Endothelial Cells; Fluoresceins; Free Radical Scavengers; Gene Expression Regulation; Humans; Hydrazines; Indicators and Reagents; Inflammation; Ketocholesterols; Monocytes; NF-kappa B p50 Subunit; Nifedipine; Picrates; Protein Transport; Reactive Oxygen Species; RNA, Messenger; Time Factors; Tumor Necrosis Factor-alpha; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2006 |